BRIXADI FDA approval date

The FDA approved BRIXADI on 23 May 2023.

FDA approval date
23 May 2023

Drug identity has not yet been verified against registry records

Also recorded as BUPRENORPHINE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-05-23DayBRIXADIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA210136", "applicant_as_listed_by_fda": "BRAEBURN", "brand_names": ["BRIXADI"], "active_ingredients": ["BUPRENORPHINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230523", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026